The authors of the published paper [1] would like to correct Table 1. The sixth row in the second column should have been Amphotericin B Lipid Complex (ABLC). Therefore, Table 1 should read as follows:
Table 1.
Treatment recommendations for invasive aspergillosis.
We apologize for any inconvenience caused to readers. The manuscript will be updated and the original will remain available on the article webpage.
Conflicts of Interest
The authors declare no conflict of interest.
Reference
Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi2016, 2, 25. [Google Scholar] [CrossRef]
Table 1.
Treatment recommendations for invasive aspergillosis.
Table 1.
Treatment recommendations for invasive aspergillosis.
Recommendation
Drug
Dosing
Comments
Primary
Voriconazole
6 mg/kg IV every 12 h times two then 4 mg/kg IV every 12 h
Oral therapy at mg/kg dosing or 200–300 mg every 12 h; TDM required
Alternatives
Lipsosomal amphotericin B (L-AMB)
3–5 mg/kg/day IV
Isavuconazole
200 mg every 8 h IV or PO times six then 200 mg daily IV or PO
Need for TDM remains undefined
Voriconazole plus Anidulafungin
Vorizonazole as above plus Anidulafungin 200 mg IV daily times one then 100 mg IV daily
Combination therapy considered in severe disease and with hematologic malignancy
Amphotericin B Lipid Complex (ABLC)
5 mg/kg/day IV
Secondary
Caspofungin
70 mg IV daily times one then 50 mg IV daily
Monotherapy as salvage
Posaconazole
Oral suspension: 200 mg PO every 8 h, Tablet: 300 mg PO every 12 h times two then 300 mg PO daily, Intravenous: 300 mg IV every 12 h times two then 300 mg IV daily
Caution in use of tablet formulation with acid suppression; TDM required
